Chest
-
Critical Care CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 04:15 PM - 05:15 PMINTRODUCTION: The use of recombinant activated Factor VIIa(rFVIIa) was first approved in the United States in 1999 for treating bleeding episodes in patients with congenital and acquired Hemophilia A and B, hemophilia with inhibitors to factor VIII and IX, and surgical prophylaxis. The indications have been limited due to its risk of thrombosis. We are reporting a case of rFVIIa use for life threatening diffuse alveolar hemorrhage. ⋯ The following authors have nothing to disclose: Felix Hernandez, Michael Alvarez, Jose Ramirez, Gustavo FerrerNo Product/Research Disclosure Information.
-
Critical Care Posters IIISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To identify risk factor on admission in patients with acute GIH, to predict need of critical care monitoring. ⋯ The following authors have nothing to disclose: Amitesh Agarwal, Marlow Hernandez, Gustavo FerrerNo Product/Research Disclosure Information.
-
Asthma PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Children with asthma frequently seen in the emergency room and hospital often lack care coordination and are discharged to poorly resourced and/or chaotic environments. Affected caregivers may benefit from a central healthcare liaison who equips them to navigate clinical asthma management. The purpose of this study is to determine whether asthma education and care coordination conducted by practice-based asthma navigators improves asthma control for children. This is a preliminary report of the first 76 families enrolled and followed for one year. ⋯ The following authors have nothing to disclose: Tyra Bryant-Stephens, Caroline WestNo Product/Research Disclosure Information.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Lymphomatoid granulomatosis is a rare lymphoproliferative angio destructive disease associated systemic Epstein-Barr virus infection, characterized by predominant pulmonary involvement and extrapulmonary too, with uncertain malignant potential. ⋯ This disease is usually progressive and fatal. The mortality rate varies from 63-90% at 5 years, however the clinical course is variable reported prolonged disease and spontaneous resolutionReference #1: Lymphocytic interstitial pneumonia and other lymphoproliferative Disorders in the long run. Nicholson AG Semin Respir Crit Care Med. 2001 22 (4): 409)DISCLOSURE: The following authors have nothing to disclose: Alina Pirvu, Claudia Toma, Ionela Belaconi, Miron Alexandru BogdanNo Product/Research Disclosure Information.
-
Rare Disease Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Amyloidosis is a consequent of extracellular deposition of insoluble fibrillar proteins. It could present either localized or systemic. Half of the cases have involvement of the trachea, bronchi or the lung parenchyma. We report a case of multinodular pulmonary amyloidosis and its course over six years. ⋯ Involvement of lung as a single organ in amyloidosis is very rare and should always raise a concern for pulmonary metastasis of a distal neoplasm. Moreover, pulmonary amyloidosis should always be in differential when managing multinodular lung lesions.Reference #1: Zhang LA. et al. Mimicking pulmonary multiple metastatic tumors: A case of primary nodular parenchymal pulmonary amyloidosis with review of the literature. Oncology Letters 4: 1366-1370, 2012DISCLOSURE: The following authors have nothing to disclose: Mehdi Shahidi, Mingchen Song, Viral Doshi, Robel HaileNo Product/Research Disclosure Information.